CAS No.128779-47-5 Pharmaceutical Intermediates

Introducing LCZ696 INT, an innovative pharmaceutical compound designed to change the landscape of cardiovascular disease treatment. As a product of our advanced manufacturing facilities, LCZ696 INT combines cutting-edge production technology with rigorous quality assurance to deliver superior efficacy and safety. Our integrated manufacturing and trading company is committed to providing high-quality pharmaceutical solutions that meet the needs of healthcare providers and patients. With its unique formulation and proven benefits, LCZ696 INT has the potential to become a cornerstone in the management of heart failure and hypertension.

product details

Product details

Product detail

LCZ696 INT, also known as sacubitril/valsartan, is a new angiotensin receptor neprilysin inhibitor (ARNI) that has been clinically proven to be effective in the treatment of heart failure with reduced ejection fraction (HFrEF). ). This innovative compound combines the dual effects of neprilysin inhibition and angiotensin receptor blockade to provide a comprehensive treatment approach for cardiovascular health. By addressing multiple pathways in heart failure, LCZ696 INT offers significant therapeutic advantages over traditional treatments.

product detail

CAS No.	40856-44-8
EINECS	609-874-3
Formula	C9H11NO2
Molecular Weight	165.19
Appearance	White to Off-White solid
Purity	≥98%
Type	Pharmaceutical Intermediates

Physical and chemical properties

LCZ696 INT has unique physical and chemical properties that contribute to its effectiveness in pharmaceutical applications:

- Molecular Structure: This compound has a complex molecular structure, which favors its dual mechanism of action. This structure allows optimal interaction with biological targets, thereby enhancing their therapeutic efficacy.

- Solubility: LCZ696 INT exhibits excellent solubility in both water and organic solvents, making it easy to formulate into various dosage forms. This solubility ensures that the active ingredients are easily absorbed by the body.

- STABILITY: The compound remains stable across a wide range of pH values, which is critical to maintaining its potency and efficacy throughout its shelf life. This stability minimizes the risk of degradation and ensures consistent performance of drug formulations.

- Safety: A large number of clinical studies have shown that LCZ696 INT has good safety and controllable side effects. This makes it a reliable option for patients requiring long-term treatment for cardiovascular disease.

Advantages

1. Dual Mechanism of Action: The combination of neprilysin inhibition and angiotensin receptor blockade enables LCZ696 INT to provide comprehensive cardiovascular protection. This dual effect not only lowers blood pressure, but also promotes vasodilation, improves cardiac output and reduces the burden on the heart.

2. Improved patient outcomes: Clinical trials have shown that cardiovascular mortality and heart failure hospitalization rates were significantly reduced in patients treated with LCZ696 INT. This means patients’ quality of life and functional abilities are improved.

3. Multifunctional Applications: Although LCZ696 INT is primarily used to treat heart failure, its unique mechanism may also bring potential benefits to the treatment of other cardiovascular diseases, making it a multifunctional addition to the pharmaceutical market.

4. Cost Effectiveness: By improving treatment efficacy, LCZ696 INT can reduce overall healthcare costs. Reduced hospitalization rates and improved patient outcomes help manage cardiovascular disease in a more cost-effective manner.

Manufacturing excellence

As a factory integrating production and trading, our commitment to quality remains consistent. We adhere to strict Good Manufacturing Practices (GMP) to ensure that every batch of LCZ696 INT meets the highest standards of purity and potency. Our advanced manufacturing process utilizes state-of-the-art technology and equipment, allowing us to efficiently produce LCZ696 INT while maintaining strict quality control measures.

Committed to innovation

Our company is committed to ongoing research and development in an effort to enhance our product offerings and meet the ever-changing needs of the pharmaceutical industry. By investing in innovative technologies and forming partnerships with leading research institutions, we aim to remain at the forefront of pharmaceutical advancements.

In summary

In summary, LCZ696 INT represents a major advance in the treatment of cardiovascular disease. With its unique dual mechanism of action, proven efficacy and favorable safety profile, it will have a lasting impact on patient care. Our commitment to quality manufacturing and innovation ensures healthcare providers can trust LCZ696 INT as a reliable choice for their patients. Choose LCZ696 INT and create a healthier future together - because every heartbeat matters.